Caribou Biosciences
Caribou Biosciences' revenue rose 11.7% to $11 million in fiscal 2025. Its operating margin was −1,329.4%, up from −1,667.2% a year earlier. Free cash flow was −$112 million. The diluted share count rose 3.4%.
Operating margin is operating income as a share of revenue. Free cash flow is cash from operations minus capital spending. Return on equity is net income as a share of shareholders' equity. Market cap is the last closing share price times the latest diluted share count, so it is approximate. P/E is the last close divided by diluted earnings per share over the last four quarters, or the latest fiscal year where the quarters aren't available; there is none when the company made a loss.
Charts show fiscal years, from the 10-K filings.
What Caribou Biosciences does
Caribou Biosciences is a clinical-stage biotechnology company, which means it is still testing its medicines in people and has none on the market. It develops cell therapies for blood cancers using its own CRISPR-based gene-editing technology, called chRDNA. Its therapies are "off-the-shelf" CAR-T cells: immune cells made in advance from healthy donors rather than from each patient.
It has two candidates in clinical trials. Vispa-cel targets CD19 and has been tested in relapsed or refractory B cell non-Hodgkin lymphoma. CB-011 targets BCMA and is being tested in relapsed or refractory multiple myeloma. The FDA has granted vispa-cel several special designations, including fast track and orphan drug status for certain lymphomas.
Because it has no approved product, it has no product sales. The company says it will need substantial additional financing to run a planned pivotal trial of vispa-cel, the large late-stage study that regulators require for approval.
Its biggest risks, as it describes them
- Continued operating losses and uncertainty about whether it will ever be profitable.
- Needing substantial new financing, which could dilute shareholders or limit its operations.
- Its candidates being years from market, if ever, and depending on unproven gene-editing technology.
- Complex manufacturing of cell therapies that could delay trials.
- Trials failing to show safety and effectiveness, or the FDA not approving its therapies.
Income statement
Caribou Biosciences lost money in fiscal 2025: a net loss of $148 million.
Returns on capital
Balance sheet
Five years at a glance
| Fiscal year end | FY21 | FY22 | FY23 | FY24 | FY25 |
|---|---|---|---|---|---|
| Cash and short-term investments | 414 | 317 | 372 | 249 | 143 |
| Debt incl. finance leases | — | — | — | — | — |
| Net debt (negative means net cash) | — | — | — | — | — |
| Net debt to EBITDA | — | — | — | — | — |
| Debt to equity | — | — | — | — | — |
| Interest coverage | −8,372.4x | — | — | — | — |
| Current ratio | 15.2x | 9.2x | 12.0x | 7.2x | 5.7x |
| Quick ratio | 15.2x | 9.2x | 12.0x | 7.2x | 5.7x |
Cash flow
Projections
Project Caribou Biosciences' revenue, net income and earnings per share five years ahead in a bull, a base and a bear case with your own figures, and see the share prices your P/E estimates give them, or value it with a discounted cash flow model. Every projected figure is yours: it is not a forecast of ours.
Insider trades
Over the 12 months between November 20, 2025 and November 19, 2026, no insider bought Caribou Biosciences shares on the open market, and 3 insiders sold $33,875, $15,687 of it under trading plans set up in advance.
| Date | Insider | Trade | Shares | Price | Value | Filing |
|---|---|---|---|---|---|---|
| Feb 25, 2026 | Timothy P KellyChief Technology Officer | Sold | 6,228 | $1.93 | $12,020 | Form 4 |
| Feb 24, 2026 | Barbara G McClungChief Legal Officer | Sold plan | 6,938 | $1.96 | $13,598 | Form 4 |
| Feb 24, 2026 | Timothy P KellyChief Technology Officer | Sold | 3,147 | $1.96 | $6,168 | Form 4 |
| Feb 24, 2026 | Tina M. AlbertsonChief Medical Officer | Sold plan | 1,066 | $1.96 | $2,089 | Form 4 |
Indicators
Four widely used measures, worked out from the company's filings. The cutoffs are the ones their authors or users go by, not a verdict of ours.
| Indicator | FY23 | FY24 | FY25 |
|---|---|---|---|
| Piotroski F-score | — | — | — |
| Rule of 40 | −155.4% | −1,502.7% | −995.2% |
| Altman Z'' | 6.71 | 0.11 | −9.88 |
| Accruals ratio | −2.2% | −2.9% | −15.2% |
The nine F-score tests
| Test | FY23 | FY24 | FY25 |
|---|---|---|---|
| Net income is positive | Fail | Fail | Fail |
| Cash from operations is positive | Fail | Fail | Fail |
| Return on assets rose | Fail | Fail | Fail |
| Cash from operations exceeds net income | Pass | Pass | Pass |
| Debt fell relative to assets | — | — | — |
| Current ratio rose | Pass | Fail | Fail |
| Share count didn't rise | Fail | Fail | Fail |
| Gross margin rose | — | — | — |
| Revenue rose relative to assets | Pass | Fail | Pass |
| F-score | — | — | — |
Compare
Put Caribou Biosciences side by side with any other company we cover: revenue, growth, margins, cash flow and returns, with ten years of charts.
Similar companies
| Company | Year | Revenue growth | Operating margin | Free cash flow margin | Return on capital | Net debt to EBITDA | F-score | Compare |
|---|---|---|---|---|---|---|---|---|
| Caribou Biosciences | FY25 | 11.7% | −1,329.4% | −1,006.8% | — | — | — | |
| TScan Therapeutics | FY25 | 266.6% | −1,315.4% | −1,353.3% | — | — | 3 | Compare |
| Alpha Cognition | FY25 | — | −221.7% | −202.3% | — | — | — | Compare |
| Janux Therapeutics | FY25 | −5.5% | −1,576.7% | −832.8% | — | — | — | Compare |
| Taysha Gene Therapies | FY25 | 17.3% | −1,130.7% | −960.1% | — | — | 4 | Compare |
7 years of figures
| Fiscal year | FY19 | FY20 | FY21 | FY22 | FY23 | FY24 | FY25 |
|---|---|---|---|---|---|---|---|
| Income statement | |||||||
| Revenue | 6 | 12 | 10 | 14 | 34 | 10 | 11 |
| Revenue growth | — | 113.6% | −22.4% | 44.3% | 148.9% | −71.0% | 11.7% |
| Gross profit | — | — | — | — | — | — | — |
| Research and development | 24 | 34 | 52 | 82 | 112 | 130 | 109 |
| Operating income | −34 | −36 | −67 | −106 | −116 | −167 | −148 |
| Net income | −23 | −34 | −67 | −99 | −102 | −149 | −148 |
| Diluted EPS (US$) | −2.80 | −4.01 | −2.11 | −1.64 | −1.38 | −1.65 | −1.59 |
| Diluted shares (millions) | 8 | 8 | 32 | 61 | 74 | 90 | 93 |
| Cash flow | |||||||
| Cash from operations | −32 | −33 | −32 | −91 | −93 | −138 | −111 |
| Capital expenditure | 1 | 0 | 2 | 6 | 12 | 5 | 1 |
| Free cash flow | −33 | −34 | −35 | −97 | −105 | −143 | −112 |
| Dividends paid | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Share buybacks | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Acquisitions | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Stock-based compensation | 1 | 1 | 3 | 12 | 14 | 17 | 13 |
| Balance sheet at fiscal year end | |||||||
| Cash and short-term investments | 41 | 16 | 414 | 317 | 372 | 249 | 143 |
| Debt incl. finance leases | — | — | — | — | — | — | — |
| Total assets | — | 36 | 442 | 374 | 432 | 313 | 175 |
| Total liabilities | — | 18 | 54 | 73 | 64 | 60 | 53 |
| Shareholders' equity | 8 | −23 | 388 | 301 | 368 | 253 | 122 |
| Margins and ratios | |||||||
| Gross margin | — | — | — | — | — | — | — |
| Operating margin | −592.7% | −292.2% | −697.8% | −768.2% | −336.6% | −1,667.2% | −1,329.4% |
| Net margin | −404.8% | −277.6% | −697.3% | −717.8% | −296.1% | −1,492.0% | −1,327.4% |
| Free cash flow margin | −568.2% | −271.3% | −360.9% | −703.3% | −304.3% | −1,431.7% | −1,006.8% |
| Rule of 40 (growth + FCF margin) | — | −157.7% | −383.3% | −659.0% | −155.4% | −1,502.7% | −995.2% |
| Return on capital | — | — | — | — | — | — | — |
| Return on equity | — | — | −36.7% | −28.9% | −30.5% | −48.0% | −79.0% |
| Return on assets | — | — | −28.0% | −24.4% | −25.3% | −40.0% | −60.6% |
| Net debt to EBITDA | — | — | — | — | — | — | — |